

Table S1. Multivariable Cox regression of factors in NAPOLI-1 nomogram (n = 473)

	HR	(95% CI)	Wald p-Value
Baseline ECOG Performance Score, ≥ 1 vs. 0	0.840	(0.642-1.100)	0.2063
Baseline albumin, ≥ 4 g/dL vs. < 4 g/dL	0.721	(0.568-0.915)	0.0073
Neutrophil lymphocyte ratio, ≤ 5 vs. > 5	0.650	(0.511-0.827)	0.0004
No liver metastasis vs. liver metastases	0.653	(0.509-0.839)	0.0008
Baseline CA19-9 ≤ 1542 vs. > 1542	0.574	(0.457-0.721)	< 0.0001
Stage I to III vs. stage IV at diagnosis	0.763	(0.594-0.979)	0.0338
Body mass index > 25 vs. ≤ 25	1.035	(0.764-1.403)	0.8201

Table S2. Multivariable Cox regression of other covariates with NAPOLI-1 nomogram risk score (n =473)

	HR	(95% CI)	Wald p-Value
NAPOLI-1 nomogram risk score	0.996	(0.995-0.997)	<0.0001
Age>65 vs. ≤65	1.255	(0.989-1.593)	0.0612
Gender, male vs. female	1.273	(1.009-1.607)	0.0412
Relative dose intensity at 6-week	0.991	(0.989-0.994)	<0.0001
Primary tumor location: head of pancreas vs. other	0.912	(0.712-1.167)	0.4643
Whipple operation: yes vs. no	0.697	(0.489-0.996)	0.0476
Prior exposure of fluorouracil, yes vs. no	1.506	(1.084-2.092)	0.0145
Prior exposure of irinotecan, yes vs. no	1.259	(0.900-1.762)	0.1776
Prior exposure of platinum, yes vs. no	1.253	(0.965-1.626)	0.0898
Number of metastatic sites	1.075	(0.938-1.233)	0.2949

Table S3. Model in patients without missing value (n=264)

Model 1 NAPOLI-1 nomogram			Model 2 NAPOLI-1 nomogram and cumulative dose		
Parameter	HR (95%CI)	P-value	Parameter	HR (95%CI)	P-value
Nomogram risk score	0.996 (0.995-0.997)	<0.0001	Nomogram risk score	0.996 (0.995-0.997)	<0.0001
			Relative dose intensity at 6-week >80%	Reference	-
			Relative dose intensity at 6-week 60-80%	1.310 (0.813- 2.110)	0.2658
			Relative dose intensity at 6-week <60%	2.092 (1.332- 3.287)	0.0013